Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Disclosing pathogenic genetic variants to research participants: Quantifying an emerging ethical responsibility

Disclosing pathogenic genetic variants to research participants: Quantifying an emerging ethical responsibility

Thumbnail Image
Download
Name

Cassa-2012-Disclosing pathogenic genetic variants to research participants.pdf

Size

267.68 KB

Format

Adobe PDF

Checksum (MD5)

ab1ada114915d16572e11456e305d9f5

Author(s)
Cassa, Christopher A.
•
Savage, Sarah K.
•
Taylor, Patrick L.
•
Green, Robert C.
•
McGuire, Amy L.
•
Mandl, Kenneth D.
Date Issued
December 2011
Journal
Genome Research
Publisher
Cold Spring Harbor Laboratory Press
Citation
Cassa, C. A. et al. “Disclosing Pathogenic Genetic Variants to Research Participants: Quantifying an Emerging Ethical Responsibility.” Genome Research 22.3 (2011): 421–428. Web.© 2012 by Cold Spring Harbor Laboratory Press.
Version
Final published version
Abstract
There is an emerging consensus that when investigators obtain genomic data from research participants, they may incur an ethical responsibility to inform at-risk individuals about clinically significant variants discovered during the course of their research. With whole-exome sequencing becoming commonplace and the falling costs of full-genome sequencing, there will be an increasingly large number of variants identified in research participants that may be of sufficient clinical relevance to share. An explicit approach to triaging and communicating these results has yet to be developed, and even the magnitude of the task is uncertain. To develop an estimate of the number of variants that might qualify for disclosure, we apply recently published recommendations for the return of results to a defined and representative set of variants and then extrapolate these estimates to genome scale. We find that the total number of variants meeting the threshold for recommended disclosure ranges from 3955–12,579 (3.79%–12.06%, 95% CI) in the most conservative estimate to 6998–17,189 (6.69%–16.48%, 95% CI) in an estimate including variants with variable disease expressivity. Additionally, if the growth rate from the previous 4 yr continues, we estimate that the total number of disease-associated variants will grow 37% over the next 4 yr.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Civil and Environmental Engineering
Terms of Use
Creative Commons Attribution Non-Commercial
http://creativecommons.org/licenses/by-nc/3.0
Persistent DSpace Link
http://hdl.handle.net/1721.1/76767
DOI of Published Version
https://doi.org/10.1101/gr.127845.111
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.